Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) Target Price at $17.33

Elanco Animal Health Incorporated (NYSE:ELAN) has received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $17.3333.

ELAN has been the subject of a number of research analyst reports. Wall Street Zen upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Leerink Partnrs raised Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 17th. Leerink Partners upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. Piper Sandler lifted their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, August 11th. Finally, UBS Group boosted their target price on Elanco Animal Health from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, August 8th.

Elanco Animal Health Stock Down 0.6%

ELAN opened at $17.80 on Friday. The stock has a market capitalization of $8.84 billion, a price-to-earnings ratio of 20.70, a price-to-earnings-growth ratio of 3.32 and a beta of 1.66. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $18.08. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The business has a 50-day moving average of $15.16 and a two-hundred day moving average of $12.52.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.19 billion. During the same period last year, the company earned $0.30 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. boosted its position in Elanco Animal Health by 53.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 211,904 shares of the company’s stock worth $2,566,000 after purchasing an additional 73,838 shares during the period. Invesco Ltd. boosted its position in shares of Elanco Animal Health by 10.6% in the fourth quarter. Invesco Ltd. now owns 536,391 shares of the company’s stock worth $6,496,000 after buying an additional 51,233 shares during the period. Mariner LLC boosted its position in shares of Elanco Animal Health by 79.6% in the fourth quarter. Mariner LLC now owns 56,193 shares of the company’s stock worth $680,000 after buying an additional 24,901 shares during the period. First Trust Advisors LP grew its stake in shares of Elanco Animal Health by 508.2% in the fourth quarter. First Trust Advisors LP now owns 133,038 shares of the company’s stock valued at $1,611,000 after buying an additional 111,163 shares in the last quarter. Finally, Stifel Financial Corp raised its holdings in shares of Elanco Animal Health by 103.6% during the 4th quarter. Stifel Financial Corp now owns 228,277 shares of the company’s stock valued at $2,764,000 after buying an additional 116,175 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.